SCHEMBL2366464

SCHEMBL2366464

Cc1cc(C2CC2)cnc1N1CCN(C(=O)c2ccc(N3C(=O)OC[C@H]3C)cc2NS(C)(=O)=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 2/20 0.35
SLC6A5 Q9Y345 1/20 0.35
IDH1 O75874 3/20 0.31
GPR6 P46095 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
TP53 P04637 5/20 0.31
MAPT P10636 3/20 0.31
OPRK1 P41145 1/20 0.31
PIK3CA P42336 2/20 0.31
LMNA P02545 3/20 0.30
THRB P10828 2/20 0.30
FASN P49327 1/20 0.30
PIK3CD O00329 1/20 0.30
MAP4K1 Q92918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366141 0.91 SLC6A9 (0.37) SLC6A9SLC6A5IDH1MMP2MMP9
SCHEMBL2365925 0.88 LMNA (0.35) SLC6A9SLC6A5IDH1GPR6TP53
SCHEMBL2365935 0.88 LMNA (0.35) SLC6A9SLC6A5IDH1GPR6TP53
Hydrochloric Acid SCHEMBL2366022 0.88 SLC6A9 (0.38) SLC6A9SLC6A5IDH1GPR6TP53
SCHEMBL2365978 0.86 PIK3CD (0.36) SLC6A9SLC6A5MMP2MMP9TP53
Hydrochloric Acid SCHEMBL2366527 0.86 IDH1 (0.38) SLC6A9SLC6A5IDH1TP53MAPT
Hydrochloric Acid SCHEMBL2366534 0.86 IDH1 (0.38) SLC6A9SLC6A5IDH1TP53MAPT
SCHEMBL2366448 0.84 KDM4E (0.36) IDH1MAPTPIK3CALMNAFASN
SCHEMBL2366456 0.84 KDM4E (0.36) IDH1MAPTPIK3CALMNAFASN
SCHEMBL2366184 0.83 ALDH1A1 (0.39) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 SLC6A9 446/4885SLC6A5 2726/4885IDH1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.